Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-48124
J Neuroimmunol 2013 Jul 15;2601-2:107-16. doi: 10.1016/j.jneuroim.2013.03.003.
Show Gene links Show Anatomy links

Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4.

Miyazaki K , Abe Y , Iwanari H , Suzuki Y , Kikuchi T , Ito T , Kato J , Kusano-Arai O , Takahashi T , Nishiyama S , Ikeshima-Kataoka H , Tsuji S , Arimitsu T , Kato Y , Sakihama T , Toyama Y , Fujihara K , Hamakubo T , Yasui M .


???displayArticle.abstract???
Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.

???displayArticle.pubmedLink??? 23746426
???displayArticle.link??? J Neuroimmunol


Species referenced: Xenopus
Genes referenced: aqp4